Literature DB >> 2023068

Childhood melanoma.

W J Temple1, R H Mulloy, F Alexander, L H Marx, M Jenkins, L M Jerry.   

Abstract

In melanoma patients, the prognostic value of tumor depth, Clark's level, the presence of ulceration, and regional involvement have not been clearly documented in the pediatric population. This report correlates these factors in a population-based study of patients under the age of 20 years. Of the initial 35 melanoma patients registered in southern Alberta with the Alberta Cancer Board, 14 were found on review to have a diagnosis other than melanoma. In the remaining 21 cases the diagnosis of melanoma was confirmed. There was a suggestion that patients with deeper lesions had a worse prognosis, but this was statistically confirmed only using Clark's levels. The children were then compared with all melanoma patients diagnosed in southern Alberta over the same time period. There was no difference in tumor depth, Clark's level, ulceration, regional involvement, or survival between these two groups. The natural history in children appears to be similar to that of the adult population, contrary to previous reports suggesting a markedly worse prognosis.

Entities:  

Mesh:

Year:  1991        PMID: 2023068     DOI: 10.1016/0022-3468(91)90893-x

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  2 in total

1.  Pediatric melanoma: analysis of an international registry.

Authors:  Bruce J Averbook; Sandra J Lee; Keith A Delman; Kenneth W Gow; Jonathan S Zager; Vernon K Sondak; Jane L Messina; Michael S Sabel; Mark R Pittelkow; Phillip M Ecker; Svetomir N Markovic; Susan M Swetter; Sancy A Leachman; Alessandro Testori; Clara Curiel-Lewandrowski; Ronald S Go; Drazen M Jukic; John M Kirkwood
Journal:  Cancer       Date:  2013-09-10       Impact factor: 6.860

2.  Prepubertal melanoma in a medium-sized congenital naevus.

Authors:  L De Raeve; W Danau; A De Backer; J Otten
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.